Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450415 | 0.88 | ALDH1A1 (0.70) | RAB9AKAT6ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2650229 | 0.88 | POLB (0.72) | RAB9ASMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL5148434 | 0.85 | ALDH1A1 (0.66) | RAB9AKAT6ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL12259165 | 0.80 | KMT2A (0.72) | RAB9ASMN1; SMN2ALDH1A1NPC1POLB | |
| SCHEMBL12857742 | 0.80 | RAB9A (1.00) | RAB9ASMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL20233039 | 0.79 | RAB9A (0.69) | RAB9AKAT6ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL11815392 | 0.79 | KMT2A (0.65) | RAB9ASMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL6448644 | 0.79 | CA1 (0.62) | RAB9ASMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL12323189 | 0.79 | NPC1 (0.75) | RAB9ASMN1; SMN2ALDH1A1NPC1GAA | |
| SCHEMBL17772176 | 0.79 | HTT (0.63) | RAB9ASMN1; SMN2ALDH1A1NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | RAB9A 2483/4885KAT6A 1911/4885SMN1; SMN2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.